Accretion Nutraveda IPO Review

Live status (1 Jul 2026): This one has been a genuine winner, a rarity among recent SME listings. After a strong debut on 4 February 2026, when it listed at Rs 191, a 48% premium over the Rs 129 issue price, the stock has kept climbing to around Rs 269. That means IPO investors have more than doubled their money, with the stock up over 100% from the issue price.

About the Company

Reach for an Ayurvedic liver tonic, a joint care capsule or a wellness powder, and there is a good chance a contract manufacturer made it for the brand on the label. Accretion Nutraveda is one of those makers, producing Ayurvedic and nutraceutical products for other companies to sell.

Set up in 2021 and based in Ahmedabad, Gujarat, it works as a contract development and manufacturing organisation, or CDMO. In plain terms, brands come to it with a product idea and it handles the formulation and manufacturing. It makes a wide range of dosage forms, including tablets, capsules, oral liquids, powders, oils and topical items like balms and creams, aimed at areas such as liver care, women's health, bone and joint health, cognitive support and respiratory wellness.

It sells mostly in India, with growing direct exports to markets like Sri Lanka, Singapore and the USA. Its manufacturing facility in Gujarat, though modest in size, carries a strong set of quality certifications including WHO GMP, FSSC 22000, ISO and Halal. You can follow its live price and financial updates on the IPO GMP Live homepage. It is a small but quality focused operation, with only around 18 employees.

Financial Snapshot

The growth here is real and, importantly, it comes with healthy margins, which sets it apart from many small manufacturers. Revenue rose from Rs 5 crore in FY24 to Rs 16 crore in FY25, and the first half of FY26 added Rs 14 crore, so it is on track to grow strongly again. Profit followed, from Rs 0.82 crore to Rs 2.61 crore, with Rs 2.33 crore in the first half of FY26 alone.

What stands out is the profitability. A net margin around 16% and a return on equity in the mid teens are genuinely good for a CDMO, and far healthier than the thin margins you see in commodity businesses. This is a value added, quality driven operation, not a low margin trader.

Now the caution, which is all about price. At the issue price the stock was valued at around 26 times earnings. After the run to Rs 269, that multiple has expanded to roughly 37 times, and the market cap is now near Rs 190 crore at the current price, not the far lower figure shown at the issue price. So this is a good business, but it is no longer cheap. You are paying a premium multiple for a company that, while growing nicely, is still very small, with only about Rs 16 crore of annual revenue behind it.

Strengths

The most attractive thing about Accretion is the combination of growth and margins. Revenue has grown several fold in two years while keeping a net margin around 16% and a healthy return on equity, which is a rare and genuinely good mix for a small manufacturer. It operates in the Ayurveda and nutraceutical wellness space, which has a strong long term demand tailwind as more consumers turn to preventive and natural health products.

Beyond that, it runs an asset light CDMO model, making products for other brands rather than carrying big inventory risk of its own, and its facility holds a serious set of quality certifications including WHO GMP, FSSC 22000, ISO and Halal, which matter for winning pharma and export clients. Its growing exports to Sri Lanka, Singapore and the USA add another leg to the story, and the IPO itself rewarded investors handsomely, listing up 48% and then doubling.

Risks

The clearest risk is the valuation after such a strong run. At around 37 times earnings, a lot of future growth is already priced in, and the stock has moved from Rs 129 to nearly Rs 300 at its peak, so buying now means paying up. Any stumble in growth could see the premium multiple contract quickly.

The other concerns come from its size and youth. This is a tiny company, with roughly Rs 16 crore of revenue and only about 18 employees, and it was incorporated only in 2021, so it has a very short track record. As a CDMO it depends on a limited set of clients, so losing even one could hurt, and as a thinly traded SME the stock is volatile, having swung between Rs 150 and Rs 300 within its short listed life. Promoter holding has also reduced since the IPO, which is worth keeping an eye on.

Should You Buy, Hold, or Sell?

The IPO is done and it has been a big win for those who got in at Rs 129. This is now a call on a quality but richly valued small cap around Rs 269.

Conservative investors are better off waiting. The business is good, but around 37 times earnings on a tiny revenue base is not a low risk entry, and a cheaper opportunity may come during one of the stock's frequent swings.

Moderate investors who own it from the IPO can reasonably hold, given the growth and margins, and might even book part of the large gain to lock in profit, while letting the rest run.

Aggressive investors who like the Ayurveda and nutraceutical theme can consider it, but ideally on dips rather than chasing after a double, and with the small size and rich valuation clearly in mind.

My honest read is that this is one of the better small businesses to come through the SME route lately, with real growth and real margins, but the easy money has been made. The quality is genuine, the price is now full, so it is best approached patiently rather than chased.

IPO Objects of the Issue

This was a fully fresh issue of about Rs 23.53 crore, with no offer for sale, so all the money went to the company. The largest chunk, around Rs 8.03 crore, goes towards machinery for a new manufacturing setup, with a further Rs 4.22 crore for automating the existing unit. The rest is split between working capital of about Rs 5.50 crore, general corporate purposes and issue expenses. In short, most of the money is going into expanding and modernising capacity, which fits a growing manufacturer.

Contact Details

Accretion Nutraveda Ltd. Ahmedabad, Gujarat (manufacturing facility in Gujarat) Business: contract development and manufacturing of Ayurvedic and nutraceutical products

IPO Registrar - KFin Technologies Ltd. Phone: 040-6716 2222 Email: einward.ris@kfintech.com Website: www.kfintech.com

Lead Manager: Sobhagya Capital Options Pvt. Ltd. Listing exchange: BSE SME.

This page is not investment advice. GMP is indicative only and unofficial. Please consult a SEBI registered financial advisor before investing.